According to Diabetes and Metabolism
, treatment with xenical reduces the incidence of type 2 diabetes in people who already have impaired glucose tolerance. And in those who already have type 2 diabetes, it has enabled them to lower their required dose of metformin, sulfonylureas, and/or insulin. Of concern, because diabetes patients are at greater risk of cardiovascular disease, it was also noted that it helped reduce their total and LDL cholesterols and other lipid markers and decreased inflammation associated with heart attack risk.
In the Prevention of Diabetes in Obese Subjects study, xenical reduced the incidence of diabetes from 9% to 6% compared to placebo, according to Diabetes Care. However, analysis of three other trials reported a nonsignificant reduction in the incidence of type 2 from 2% to 0.6% with orlistat, as reported in the Archives of Internal Medicine
Nonetheless, a report in the Journal of the American Board of Family Practitioners
noted the benefits of orlistat in helping prevent diabetes in obese patients.